APG-5918 for Nasopharyngeal Cancer

Phase-Based Progress Estimates
Yale University, New Haven, CTNasopharyngeal Cancer+13 MoreAPG-5918 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test the safety and effectiveness of a new drug, APG-5918, in people with cancer. The drug will be given orally in 28-day cycles. The trial will have two parts: first, a dose escalation to test safety, and second, a dose expansion to test effectiveness.

Eligible Conditions
  • Nasopharyngeal Cancer
  • Castration-resistant Prostate Cancer
  • Stomach Cancer
  • Ovarian Clear Cell Carcinoma
  • Mesothelioma
  • Sarcoma
  • Non-Hodgkin's Lymphoma
  • B-Cell Lymphoma
  • Epithelioid Sarcoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 28 days

28 days
Dose-limiting Toxicity (DLT)

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

Cohort 1 in Dose expansion
1 of 2
Cohort 2 in Dose expansion
1 of 2

Experimental Treatment

90 Total Participants · 2 Treatment Groups

Primary Treatment: APG-5918 · No Placebo Group · Phase 1

Cohort 1 in Dose expansion
Experimental Group · 1 Intervention: APG-5918 · Intervention Types: Drug
Cohort 2 in Dose expansion
Experimental Group · 1 Intervention: APG-5918 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

Ascentage Pharma Group Inc.Lead Sponsor
42 Previous Clinical Trials
3,077 Total Patients Enrolled
Yifan Zhai, MD, PhDStudy ChairAscentage Pharma Group Inc.
17 Previous Clinical Trials
1,181 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 13 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 3 more months.

Who else is applying?

What state do they live in?
New York33.3%
How old are they?
18 - 6550.0%
What site did they apply to?
Yale University100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Typically responds via

Frequently Asked Questions

What is the aggregate amount of people who have elected to partake in this experiment?

"Affirmative. According to the information available on clinicaltrials.gov, this medical investigation is actively seeking participants; it was first posted on September 30th 2022 and has been recently updated on November 11th 2022. A total of 90 individuals are needed from 2 trial sites." - Anonymous Online Contributor

Unverified Answer

Are any openings available for participation in this trial?

"Per the latest information from clinicaltrials.gov, this trial is open and actively recruiting participants. The initial posting took place on September 30th 2022 with a recent update happening November 11th 2022." - Anonymous Online Contributor

Unverified Answer

Is APG-5918 a potential risk factor to the general population?

"As this is an early Phase I trial, APG-5918's safety was rated at a 1. This assessment is based on limited evidence concerning the drug's effectiveness and its potential to cause harm." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.